pfizer_istock-458618835_no_limit_pictures--1

nono_limit_pictures / iStockphoto.com

30 January 2018Africa

Pfizer, patents and political quagmires

Shahan Islam said his enforcement efforts against generic producers often lead to counterarguments surrounding the price of Pfizer’s drugs and accusations that the company does not provide sufficient access to medicine for poorer people.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

Sandoz lands reduced antitrust award of $70m

Teva faces $500m fine for antitrust breaches over MS drug

Pfizer infringed haemophilia therapy patent, says court

Cooley adds ex-Gowling partner

Big Pharma counsel embrace AI but data and legal risks loom

MSN scores win in battle with Novartis over heart drug generic

HR, lobbying and business strategy…all in a day’s work for today’s counsel

LSPN Fall: Gilead GC shares top drafting tips